Recruiting
Phase 1
Phase 2

A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs

Sponsor:

Krystal Biotech, Inc.

Code:

NCT06228326

Conditions

Lung Cancer, Non-small Cell

Lung Cancer Metastatic

Solid Tumor, Adult

Advanced Cancer

Lung Cancer (NSCLC)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

KB707

Pembrolizumab (KEYTRUDA®)

Chemotherapy

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information